ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.
暂无分享,去创建一个
Andrew Z. Wang | P. Kantoff | F. Gu | R. Langer | N. Bander | O. Farokhzad | Liangfang Zhang | A. Radovic-Moreno | Kai P Yuet | M. Huynh-Le | A. Wang | Kai P. Yuet | Andrew Z. Wang
[1] Warren C W Chan,et al. Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.
[2] Robert Langer,et al. Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy , 2011 .
[3] Robert Langer,et al. Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. , 2008, ACS nano.
[4] David J Brayden,et al. Advances in PEGylation of important biotech molecules: delivery aspects. , 2008, Expert opinion on drug delivery.
[5] Robert Langer,et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.
[6] Omid C Farokhzad,et al. Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.
[7] S. Feng,et al. Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. , 2007, International journal of pharmaceutics.
[8] Joseph K Salama,et al. The concurrent chemoradiation paradigm—general principles , 2007, Nature Clinical Practice Oncology.
[9] Robert Langer,et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.
[10] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[11] J. Richie,et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Macklis,et al. Review of clinical radioimmunotherapy , 2006, Expert review of anticancer therapy.
[13] Stephen J Mather,et al. Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes , 2006, Nature Protocols.
[14] R. Langer,et al. Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies , 2005, Pharmaceutical Research.
[15] Tae Gwan Park,et al. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. , 2005, Langmuir : the ACS journal of surfaces and colloids.
[16] Omid C. Farokhzad,et al. Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.
[17] Russell J Mumper,et al. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[18] Xiaowei Liu,et al. 3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. , 2003, Cancer biotherapy & radiopharmaceuticals.
[19] D. S. Coffey,et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.
[20] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[21] I. Bernstein,et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.
[22] Y. Barenholz,et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. , 1991, British Journal of Cancer.
[23] K. Bhargava,et al. Labeling of monoclonal antibodies with radionuclides. , 1989, Seminars in nuclear medicine.
[24] R. New,et al. REDUCTION IN TOXICITY OF DOXORUBICIN BY LIPOSOMAL ENTRAPMENT , 1987, The Lancet.